Marker Therapeutics (MRKR) Cash from Investing Activities (2018 - 2023)

Marker Therapeutics (MRKR) has 6 years of Cash from Investing Activities data on file, last reported at $18.8 million in Q2 2023.

• Cash from Investing Activities for Q2 2023 came in at $18.8 million, up 928.54% year-over-year; the trailing twelve-month figure through Dec 2023 was $18.7 million (up 477.42% YoY), and the FY2023 annual result was $18.7 million, up 477.42% from the prior year.
• Cash from Investing Activities climbed to $18.8 million in Q2 2023 per MRKR's latest filing, from -$112608.0 in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $18.8 million in Q2 2023 and troughed at -$4.1 million in Q4 2020.
• A 5-year average of $53332.5 and a median of -$286484.5 in 2019 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2020 and 2023: Cash from Investing Activities slumped 31778.1% in 2020, then surged 928.54% in 2023.
• A 5-year view of Cash from Investing Activities shows it stood at -$12862.0 in 2019, then tumbled by 31778.1% to -$4.1 million in 2020, then surged by 91.47% to -$349843.0 in 2021, then soared by 63.6% to -$127342.0 in 2022, then soared by 14845.12% to $18.8 million in 2023.
• Business Quant data shows MRKR's Cash from Investing Activities at $18.8 million in Q2 2023, -$112608.0 in Q1 2023, and -$127342.0 in Q4 2022.